In my opinion there are two reasons for Dr Bruce a
Post# of 148180
One, is the patent. In my mind, the advancement of which, is a clear conflict of interest if your lab is expected to remain impartial to the results you are charged with studying and reporting.
The second is expense. IncellDX cost too much and NP said as much in a CC. That Cytodyn BOD was making a business decision. If they were making a cost savings decision, this might have been done on behalf of us shareholders and to not undertake further dilution.
One day we’ll hear the whole story, in the meantime, BOD made the decision in my opinion not NP. And the band is still together. Note: Dr Bruce’s continuous promotion of Leronlimab.
So I suggest not falling for the discordant notes, but celebrate the harmonious ones.